Question

Difficulty: Very hardPediatric Infectious Diseases

A 14-month-old girl is evaluated during morning rounds on hospital day 3. She was initially admitted due to a high fever, irritability, and an inability to bear weight on her right leg. Her medical history is significant for acute lymphoblastic leukemia, and she is currently in the maintenance phase of chemotherapy with daily oral 6-mercaptopurine and weekly oral methotrexate. Upon initial evaluation, her temperature was 39.4∘C39.4^\circ\text{C} (102.9∘F102.9^\circ\text{F}). Physical examination revealed an exquisitely tender, swollen, and erythematous right knee. Initial laboratory studies showed a leukocyte count of 4,500/mm34,500/\text{mm}^3 with an absolute neutrophil count of 1,350/mm31,350/\text{mm}^3. Arthrocentesis yielded visibly purulent synovial fluid, and she was promptly started on empiric intravenous vancomycin and cefepime.

Today, her temperature is 37.6∘C37.6^\circ\text{C} (99.7∘F99.7^\circ\text{F}) and she is clinically improving with decreased knee swelling. Synovial fluid and blood cultures obtained on admission both grow Staphylococcus aureus. Susceptibility testing demonstrates resistance to penicillin and ampicillin, but susceptibility to oxacillin, cefazolin, clindamycin, and vancomycin.

During the evaluation, the parents express concern about a recent local measles outbreak. They note that their daughter missed her 12-month well-child visit due to her cancer treatments and ask if she can receive her measles, mumps, and rubella (MMR) and varicella vaccines before discharge.

Which of the following is the most appropriate management plan regarding her antimicrobial therapy and requested immunizations?

  1. Discontinue vancomycin and cefepime, initiate intravenous cefazolin, and withhold the MMR and varicella vaccinesAnswer
  2. B
    Continue vancomycin and cefepime, and withhold the MMR and varicella vaccines
  3. C
    Discontinue vancomycin and cefepime, initiate intravenous cefazolin, and administer the MMR and varicella vaccines
  4. D
    Discontinue cefepime, continue intravenous vancomycin, and withhold the MMR and varicella vaccines
  5. E
    Discontinue vancomycin, continue intravenous cefepime, and administer the MMR and varicella vaccines

Answer

The most appropriate management is to discontinue the broad-spectrum empiric antibiotics (vancomycin and cefepime), initiate a narrow-spectrum beta-lactam (intravenous cefazolin), and withhold the requested live-attenuated vaccines.
The patient has a confirmed Methicillin-Susceptible Staphylococcus aureus (MSSA) joint infection. In accordance with antimicrobial stewardship principles, empiric broad-spectrum therapy (vancomycin and cefepime) must be narrowed once susceptibilities are known. For MSSA, antistaphylococcal beta-lactams (like cefazolin, oxacillin, or nafcillin) are superior to vancomycin, offering faster bacterial clearance and improved clinical outcomes. Additionally, the patient is on active immunosuppressive chemotherapy for leukemia. Live-attenuated vaccines, including MMR and varicella, are strictly contraindicated in severely immunocompromised individuals due to the risk of unchecked vaccine-strain viral replication. Therefore, she must transition to cefazolin and withhold the requested vaccines.

Step-by-Step Solution

1
Analyze the culture and susceptibility results.
The organism is Staphylococcus aureus susceptible to oxacillin and cefazolin, confirming it is Methicillin-Susceptible Staphylococcus aureus (MSSA).
Identifying the specific pathogen and its resistance profile is essential for de-escalating empiric therapy.
2
Apply antimicrobial stewardship principles to optimize therapy.
Transition the patient from vancomycin and cefepime to intravenous cefazolin.
Antistaphylococcal beta-lactams (like cefazolin or oxacillin) are the gold standard for MSSA, offering superior bactericidal activity and clinical outcomes compared to vancomycin. Continuing broad-spectrum cefepime is unnecessary and promotes resistance.
3
Evaluate the patient's immune status regarding vaccination eligibility.
Identify that the patient is severely immunocompromised due to active maintenance chemotherapy for acute lymphoblastic leukemia.
Immunosuppressive medications significantly impair T-cell function and cellular immunity.
4
Determine the safety of the requested 12-month immunizations.
The MMR and varicella vaccines must be withheld.
Live-attenuated vaccines are strictly contraindicated in severely immunocompromised individuals due to the risk of uncontrolled vaccine-strain viral replication and life-threatening disease.

Key Concept

Management of confirmed Methicillin-Susceptible Staphylococcus aureus (MSSA) infections and vaccination contraindications in immunocompromised pediatric patients.
Estimated Time:2m 0s
Rate this question